Governance can not rely on anti-hepatitis C virus
A clinical trial showed that hepatitis C virus and the host response in influencing the status of antiretroviral therapy has an equal status, treatment program is not just one aspect of fighting the virus, but also focus on the host (body) itself, by regulating a variety of ways in order to enhance the body’s immune status of the host of the hepatitis C virus (hcv) clearance, to gain a better efficacy.
The study to explore the different genotypes of hepatitis C virus and human leukocyte antigen (hla)-drb gene polymorphism in chronic hepatitis C (HCV) in patients with interferon combined with ribavirin for treatment response rate for the purpose of the impact of . Through the 113 patients who received interferon combined with ribavirin treatment of hepatitis C patients with genotype investigated, using gene chip technology, of which 25 cases of patients with hla-drb genotype analysis of the virus genotype and human hla allele antiviral therapy for hepatitis C in patients with reactive effects.
The results showed that different genotypes of hepatitis C virus infection on interferon combined with ribavirin treatment response rate was different, / 2b-type response rate of the highest, 57.78%; / 2a type was 47.62%; / 1a type was 46.15% , / 1b-type low response rate was only 11.76%.
Hepatitis C in patients with sex, are infected with hepatitis C virus genotype and human hla-drb alleles of three kinds of factors are related to interferon combined with ribavirin treatment response status-related. At the same time, integrated patient’s age, sex, history of blood transfusion as well as the hepatitis C virus genotypes in patients with a variety of factors on hepatitis C antiviral therapy response condition. Found that female, type hcv infections, and carrying hla-drb1 * 07 allele of the response to antiviral therapy in patients with good condition, while the male, the type hcv infections, and carrying hla-drb1 * 04 allele in patients with interferon combined Liba Waring treatment of multiple non-response.
Further compare the response of several relevant factors in fighting the virus impact the status of discovery, drb1 * 07 allele and type hcv infected with the virus against the efficacy of the factors the greatest impact (or> 15), prompted the virus and host anti-viral therapy in influencing the response status has an equal status, hepatitis C treatment programs should not simply be against the anti-virus is only one aspect, but also focus on the host itself, regulating the body through a variety of ways to enhance the host immune status of the hcv clearance, to gain a better efficacy.